Annual Cash & Cash Equivalents
$67.45 M
-$54.52 M-44.70%
December 31, 2023
Summary
- As of February 7, 2025, XERS annual cash & cash equivalents is $67.45 million, with the most recent change of -$54.52 million (-44.70%) on December 31, 2023.
- During the last 3 years, XERS annual cash & cash equivalents has risen by +$29.85 million (+79.40%).
- XERS annual cash & cash equivalents is now -44.70% below its all-time high of $121.97 million, reached on December 31, 2022.
Performance
XERS Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$59.23 M
+$1.63 M+2.83%
September 30, 2024
Summary
- As of February 7, 2025, XERS quarterly cash and cash equivalents is $59.23 million, with the most recent change of +$1.63 million (+2.83%) on September 30, 2024.
- Over the past year, XERS quarterly cash and cash equivalents has increased by +$13.09 million (+28.37%).
- XERS quarterly cash and cash equivalents is now -55.97% below its all-time high of $134.53 million, reached on June 30, 2018.
Performance
XERS Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
XERS Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -44.7% | +28.4% |
| 3 y3 years | +79.4% | +28.4% |
| 5 y5 years | +47.5% | +28.4% |
XERS Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -44.7% | +0.3% | -51.4% | +28.4% |
| 5 y | 5-year | -44.7% | +245.6% | -51.4% | +203.5% |
| alltime | all time | -44.7% | +245.6% | -56.0% | +203.5% |
Xeris Biopharma Holdings Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $59.23 M(+2.8%) |
| Jun 2024 | - | $57.60 M(-8.1%) |
| Mar 2024 | - | $62.69 M(-7.1%) |
| Dec 2023 | $67.45 M(-44.7%) | $67.45 M(+46.2%) |
| Sep 2023 | - | $46.14 M(-0.1%) |
| Jun 2023 | - | $46.17 M(-9.4%) |
| Mar 2023 | - | $50.98 M(-58.2%) |
| Dec 2022 | $121.97 M(+81.3%) | $121.97 M(+45.0%) |
| Sep 2022 | - | $84.11 M(-11.8%) |
| Jun 2022 | - | $95.34 M(-8.1%) |
| Mar 2022 | - | $103.77 M(+54.3%) |
| Dec 2021 | $67.27 M | $67.27 M(+13.1%) |
| Sep 2021 | - | $59.49 M(-6.5%) |
| Jun 2021 | - | $63.60 M(-4.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2021 | - | $66.60 M(+77.1%) |
| Dec 2020 | $37.60 M(+92.6%) | $37.60 M(-0.8%) |
| Sep 2020 | - | $37.89 M(-63.0%) |
| Jun 2020 | - | $102.47 M(+161.1%) |
| Mar 2020 | - | $39.24 M(+101.1%) |
| Dec 2019 | $19.52 M(-57.3%) | $19.52 M(-65.2%) |
| Sep 2019 | - | $56.16 M(-15.8%) |
| Jun 2019 | - | $66.67 M(+7.6%) |
| Mar 2019 | - | $61.98 M(+35.6%) |
| Dec 2018 | $45.72 M(+8.7%) | $45.72 M(-39.6%) |
| Sep 2018 | - | $75.75 M(-43.7%) |
| Jun 2018 | - | $134.53 M(+131.5%) |
| Mar 2018 | - | $58.11 M(+38.2%) |
| Dec 2017 | $42.05 M(+30.3%) | $42.05 M |
| Dec 2016 | $32.27 M | - |
FAQ
- What is Xeris Biopharma Holdings annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings annual cash & cash equivalents year-on-year change?
- What is Xeris Biopharma Holdings quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings quarterly cash and cash equivalents year-on-year change?
What is Xeris Biopharma Holdings annual cash & cash equivalents?
The current annual cash & cash equivalents of XERS is $67.45 M
What is the all time high annual cash & cash equivalents for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high annual cash & cash equivalents is $121.97 M
What is Xeris Biopharma Holdings annual cash & cash equivalents year-on-year change?
Over the past year, XERS annual cash & cash equivalents has changed by -$54.52 M (-44.70%)
What is Xeris Biopharma Holdings quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of XERS is $59.23 M
What is the all time high quarterly cash and cash equivalents for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high quarterly cash and cash equivalents is $134.53 M
What is Xeris Biopharma Holdings quarterly cash and cash equivalents year-on-year change?
Over the past year, XERS quarterly cash and cash equivalents has changed by +$13.09 M (+28.37%)